Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Novo Nordisk

253.90 DKK+3.40 %7.10, 17.10
1,108 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+3.40 %
-15.06 %
-20.93 %
+7.18 %
-21.94 %
-34.32 %
-60.65 %
-18.25 %
+20,293.57 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.13T DKK
Turnover
1.55B DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
11.01
Dividend yield-%
4.61 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
ShowingAll content types

Forum discussions
Novo has launched its new Awiqli insulin in the United States for type 2 diabetes. Its greatest advantage is that the insulin only needs to be injected once a week instead of the current daily injection. According to studies, it worked just as well in blood sugar management as daily...
8/11/2026, 1:51 PM
by Sijoittaja-alokas
34
China’s drug regulator has accepted the marketing authorization application for Novo’s oral weight-loss drug Wegovy. The company is eager to compete in the rapidly growing market, particularly against Eli Lilly. Novo Nordisk said on Thursday that China’s drug regulator accepted its...
8/27/2026, 2:43 PM
by Sijoittaja-alokas
16
Farma likes to often present these “changing improves results” findings. Paradoxically, usually changing does improve them. The explanation is the so-called regression to the mean phenomenon, meaning the switch is usually preceded by a situation where the medication hasn’t worked...
9/30/2026, 1:42 PM
by Clark kent
11
Novo’s CMD in London. The market side isn’t very convinced (-5%). The press release on the main points of the CMD was at least quite high-level jargon. Key highlights of the strategic ambitions for 20301 are: Grow and diversify pipeline Launch >5 multi-blockbusters by 2030 and deliver...
9/21/2026, 9:16 AM
by Cotr
10
Inderes Novo Nordisk enters next chapter to bring better health to more people,... Bagsværd, Denmark, 14 September 2026 – Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name, ... Corporate...
9/14/2026, 7:19 AM
by Gwertheney
10
And the German market seems to have opened today, sales are certainly massive and profits handsome, but still, there should be a couple more pillars to support this business. GLP-1 pills are not quite enough for a new rise for Novo. https://www.reuters.com/legal/litigation/novo-nordisk...
9/1/2026, 9:55 AM
by Keepitcoming
8
Novo has sued Eli Lilly over what it considers misleading advertising for a weight-loss drug. In the ad, Lilly compares Zepbound to an older and milder dose of Wegovy, even though Novo already has a newer and more effective version available. Lilly emphasizes that its comparison ...
8/13/2026, 4:25 AM
by Sijoittaja-alokas
8
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.11
2026

Interim report Q3'26

HCA Morgenbørs 07/10 - Fokus på Trophy Games i interview med CEO Søren Gleie
Video07.10.2026, 09.29 by
Victor Skriver, Rasmus Køjborg

HCA Morgenbørs 07/10 - Fokus på Trophy Games i interview med CEO Søren Gleie

Udsigt til en negativ åbning i Europa fra morgenstunden på fortsat høje renter. Fokus på Novo Nordisk (Deutsche Bank sænker kursmål). Gæst i studiet her til morgen er CEO Søren Gleie fra Trophy Games, der bl.a. vil tale om opkøbet af Playrion.

D/S NordenTrophy Games DevelopmentTormHafniaGabriel HoldingALK-AbellóGenmabNovo NordiskA.P. Møller - Mærsk
Regulatory press release05.10.2026, 14.32

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk
Regulatory press release02.10.2026, 22.53

Novo provides update on the denecimig Biologics License Application (BLA) in the US

Novo Nordisk

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release01.10.2026, 12.45

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026

Novo Nordisk
HCA Morgenbørs 01/10 - Interview med Mohammad Lauritzen fra Fibo Invest og udsigt til en negativ åbning
Video01.10.2026, 09.36 by
Jacob Frehr, Michael Friis

HCA Morgenbørs 01/10 - Interview med Mohammad Lauritzen fra Fibo Invest og udsigt til en negativ åbning

Udsigt til en negativ åbning Europa trukket af Inflationstal l ikke lagde en dæmper på renter samt tech-rally på Micron. Herhjemme fokus på Gubra, Novo, Vestas. Gæst i studiet Mohammad Lauritzen fra Fibo Invest

PandoraTormHafniaBang & OlufsenNovo NordiskZealand PharmaGubraVestas Wind SystemsDSVCarlsberg
Press release30.09.2026, 14.30

Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026

Novo Nordisk
HCA Morgenbørs 29/09 - Interview med Ole Søeberg om NVIDIA og mindre stigninger fra morgenstunden
Video29.09.2026, 09.31 by
Rasmus Køjborg, Michael Friis

HCA Morgenbørs 29/09 - Interview med Ole Søeberg om NVIDIA og mindre stigninger fra morgenstunden

Udsigt til mindre stigninger i Europa fra morgenstunden. Fokus på NKT (CMD), Boozt (opjustering) og Maersk (Hapaq-Lloyd opjustering). Gæst i studiet her til morgen er aktiestrateg Ole Søeberg fra Brock Milton Capital, der bl.a. vil tale om NVIDIA.

NvidiaNovo NordiskDSVNKTBetter CollectiveBooztFLSmidth & Co.A.P. Møller - MærskVestas Wind Systems
Regulatory press release28.09.2026, 15.49

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
HCA Morgenbørs 25/09 - Interview med Christian Stig Møller fra Nordic Bloom og rygter om aftale mellem Iran/USA
Video25.09.2026, 09.36 by
Michael Friis, Victor Skriver

HCA Morgenbørs 25/09 - Interview med Christian Stig Møller fra Nordic Bloom og rygter om aftale mellem Iran/USA

Udsigt til en positiv dag i Europa på rygter om aftale mellem Iran/USA. Fokus på Novo, Novonesis. Gæst i studiet her til morgen er Christian Stig Møller fra Nordic Bloom for at se nærmere på den næste tids US IPO's.

Novo NordiskNovonesisA.P. Møller - MærskTormPandoraVestas Wind SystemsØrsted
Press release22.09.2026, 14.00

Novo and UNICEF expand partnership to support a healthier start for more than 80 million children

Novo Nordisk
HCA Morgenbørs 22/09 – Interview med Thomas Black fra FBV og flad åbning i Europa
Video22.09.2026, 09.45 by
Michael Friis, Jacob Frehr

HCA Morgenbørs 22/09 – Interview med Thomas Black fra FBV og flad åbning i Europa

Europa ser ud til at åbne fladt op, og kan dermed ikke følge trop på de store stigninger i AI sektoren inspireret af en Muse. Herhjemme vil der blandt andet være fokus på Novo, Zealand, DSV Gæst i studiet her til morgen er Thomas Black fra FBV.

Novo NordiskDSVCadelerNordnetMetaØrstedTormZealand Pharma
Regulatory press release21.09.2026, 14.37

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release21.09.2026, 12.24

Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial

Novo Nordisk
HCA Morgenbørs 21/09 – Lars Hytting interview med fokus på Novo
Video21.09.2026, 10.01 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 21/09 – Lars Hytting interview med fokus på Novo

Lavere oliepriser, positive toner forud for Kina/USA topmøde løfter aktier fra morgenstunden. Herhjemme vil der blandt andet være fokus på Novo, Lundbeck. Gæst i studiet her til morgen er Lars Hytting fra Arthascope, hvor vi kigger nærmere på Novo.

Novo NordiskA.P. Møller - MærskGN Store NordGrønlandsbankenAlm. BrandNKTTormPandora
Press release21.09.2026, 10.00

Highlights to be presented at Novo’s Capital Markets Day 2026

Novo Nordisk
Press release18.09.2026, 12.36

Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)

Novo Nordisk
Regulatory press release17.09.2026, 16.14

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A

Novo Nordisk
Press release16.09.2026, 14.00

Novo and Anthropic will collaborate to advance drug discovery with Claude

Novo Nordisk
Press release16.09.2026, 09.00

Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026

Novo Nordisk
Regulatory press release14.09.2026, 15.13

Novo Nordisk A/S - share repurchase programme

Novo Nordisk